ALDARA

LOE Approaching

imiquimod

NDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of ZYCLARA in the treatment of AK and EGW is unknown. 12.2 Pharmacodynamics The pharmacodynamics of ZYCLARA are unknown. Imiquimod is a Toll-like receptor 7 agonist that activates immune cells. Topical application to skin is associated with increases…

Clinical Trials (5)

NCT07251413Phase 1/2Recruiting

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Started Oct 2025
18 enrolled
Cutaneous Basal Cell Carcinoma
NCT02301494N/AWithdrawn

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Started Apr 2020
NCT02130323Phase 2/3Completed

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

Started Feb 2015
22 enrolled
Cervical Intraepithelial Neoplasia
NCT03914417Phase 2Completed

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

Started Jan 2013
NCT01686152Phase 3Completed

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

Started Sep 2012
589 enrolled
Actinic Keratosis